首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1620347

全球红色生物技术市场规模：按产品类型、按应用、按最终用户、按地区、范围和预测

Global Red Biotechnology Market Size By Product Type (Gene Recombinant Drugs, Human Vaccines), By Application (Pharmacogenomics, Gene Therapy), By End-User (Research Institutes, Biopharmaceutical Industries), By Geographic Scope And Forecast

出版日期: 2024年08月31日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

红色生物技术市场规模及预测

2024年红色生物技术市场规模为5,481.1亿美元，预计到2031年将达到1,1411.7亿美元，2024年至2031年复合年增长率为9.60%。红色生物技术是生物技术的一个分支，专注于利用生物过程和生物体来开发创新药物和治疗方法。这个充满活力的领域涵盖了广泛的活动，包括药物发现和开发、生物製药、疫苗、诊断、基因治疗和组织工程。我们利用生物学方法来识别和开发针对各种疾病的新药。

透过开发更有效率、更有效的治疗方法，Red Biotechnology 可以帮助减少整体医疗保健支出。

例如，生物技术和工具的进步正在推动创新并扩大该领域的可能性。

该领域允许开发客製化治疗方法，以满足个别患者的特定需求，从而提高治疗效果。

红色生物技术的世界市场动态

塑造全球红色生物技术市场的关键市场动态

主要市场驱动因子

慢性病盛行率增加

全球慢性病的增加增加了对红色生物技术测试的需求。根据世界卫生组织 (WHO) 预测，到 2022 年，慢性病将占全球死亡人数的 71%。这一趋势推动了对先进诊断和治疗解决方案的需求。

扩大研发投入：

研发投资的增加正在推动红色生物测试的创新。美国国立卫生研究院（NIH）2023财政年度生物医学研究预算达451亿美元，较2022财年增加3.5%。资金的增加正在加速基因检测和生物标记发现的进步。

个人化医疗的趋势：

向个人化医疗的转变正在主导生物技术测试领域。美国FDA将在2023年核准26种个人化药物，占所有新药核准的39%。这一趋势正在推动伴随诊断和标靶治疗的发展。

基因编辑技术的进展：

基因编辑技术的快速进步正在推动红色生物技术测试市场的发展。根据美国国家人类基因组研究所预测，到2025年，全球CRISPR技术市场预计将达到53亿美元。这些技术创新为基因检测和治疗开发开闢了新途径。

主要问题

阻碍市场成长的监管障碍：

应对红色生物技术相关的复杂监管环境可能是一项重大课题。遵守与药物开发、临床试验和产品批准相关的法规既耗时又昂贵，阻碍了市场进入和成长。

阻碍创新的道德问题：

围绕基因改造、干细胞研究和生物技术其他方面的伦理考量可能会带来课题和限制。解决这些问题并获得公众认可对于该领域的进步至关重要。

因技术限製而导致的产品开发课题：

儘管取得了重大进展，但红色生物技术仍存在技术限制，包括扩大生产规模、确保产品一致性和克服免疫反应方面的课题。克服这些限制对于创新产品的商业化至关重要。

高成本阻碍市场渗透：

红色生物技术产品的开发和商业化成本高昂，需要在研究、开发和製造方面进行大量投资。这些高昂的成本可能会阻碍市场渗透并限制患者获得创新治疗。

主要趋势

对现场侦测的需求不断增加：

对快速现场检测的需求不断增长正在推动 Red Biotechnology 的创新。美国医疗保险和医疗补助服务中心报告称，从 2019 年到 2023 年，CLIA 豁免检测设施数量增加了 32%。这一趋势正在推动便携式且易于使用的诊断设备的发展。

推动政府措施与支持政策：

政府措施和支持政策正在推动红色生物检测市场的发展。欧盟委员会已为 "地平线欧洲" （2021-2027）拨款955亿欧元，其中大部分将用于健康研究。这些努力正在促进合作研究并加速市场成长。

扩大采用下一代定序仪 (NGS)：

扩大采用下一代定序正在推动红色生物技术测试的成长。根据国家生物技术资讯中心预测，2023年全球NGS市场规模达63亿美元。这项技术正在彻底改变基因检测和疾病诊断。

越来越重视生物标记的发现：

对生物标誌物发现的日益关注正在推动红色生物技术测试的进步。 FDA 报告称，从 2020 年到 2023 年，与生物标记相关的药物批准申请增加了 40%。这一趋势正在推动新型诊断工具和标靶治疗的发展。

Red Biotechnology Market size was valued at USD 548.11 Billion in 2024 and is projected to reach USD 1141.17 Billion by 2031 , growing at a CAGR of 9.60% from 2024 to 2031. Red biotechnology, a specialized branch of biotechnology, focuses on leveraging biological processes and organisms to develop innovative medical products and treatments. This dynamic field encompasses a wide spectrum of activities, including drug discovery and development, biopharmaceuticals, vaccines, diagnostics, gene therapy, and tissue engineering. Employing biological techniques to identify and develop novel drugs for a diverse range of diseases.

By developing more efficient and effective treatments, red biotechnology can contribute to reducing overall healthcare expenditures.

For instance, ingoing advancements in biotechnology techniques and tools are driving innovation and expanding the possibilities within this field.

The field enables the development of tailored therapies that address the specific needs of individual patients, enhancing treatment efficacy.

Global Red Biotechnology Market Dynamics

The key market dynamics that are shaping the global red biotechnology market include:

Key Market Drivers

Rising Prevalence of Chronic Diseases

: The increasing incidence of chronic diseases worldwide is propelling the demand for red biotechnology testing. According to the World Health Organization, chronic diseases accounted for 71% of global deaths in 2022. This trend is driving the need for advanced diagnostic and therapeutic solutions.

Growing Investments in R&D:

Escalating investments in research and development are fueling innovations in red biotechnology testing. The National Institutes of Health (NIH) budget for biomedical research reached $45.1 billion in fiscal year 2023, a 3.5% increase from 2022. This funding boost is accelerating advancements in genetic testing and biomarker discovery.

Dominating Trend of Personalized Medicine:

The shift towards personalized medicine is dominating the red biotechnology testing landscape. The U.S. FDA approved 26 personalized medicines in 2023, representing 39% of all new drug approvals. This trend is driving the development of companion diagnostics and targeted therapies.

Propelling Advancements in Gene Editing Technologies:

Rapid advancements in gene editing technologies are propelling the red biotechnology testing market forward. The global CRISPR technology market is projected to reach $5.3 billion by 2025, according to the National Human Genome Research Institute. These innovations are opening new avenues for genetic testing and therapy development.

Key Challenges:

Regulatory Hurdles Hindering Market Growth:

Navigating the complex regulatory landscape associated with red biotechnology can be a significant challenge. Compliance with regulations related to drug development, clinical trials, and product approval can be time-consuming and costly, hindering market entry and growth.

Ethical Concerns Hampering Innovation:

Ethical considerations surrounding genetic engineering, stem cell research, and other aspects of red biotechnology can create challenges and limitations. Addressing these concerns and obtaining public acceptance is essential for the advancement of the field.

Technological Limitations Challenging Product Development:

Despite significant advancements, there are still technological limitations in red biotechnology, such as challenges in scaling up production, ensuring product consistency, and overcoming immune responses. Overcoming these limitations is crucial for the commercialization of innovative products.

High Costs Obstructing Market Penetration:

The development and commercialization of red biotechnology products can be expensive, requiring substantial investments in research, development, and manufacturing. These high costs can limit market penetration and access to innovative treatments for patients.

Key Trends

Rising Demand for Point-of-Care Testing:

The growing demand for rapid, point-of-care testing is driving innovation in red biotechnology. The U.S. Centers for Medicare & Medicaid Services reported a 32% increase in CLIA-waived testing facilities from 2019 to 2023. This trend is fostering the development of portable and user-friendly diagnostic devices.

Propelling Government Initiatives and Supportive Policies:

Government initiatives and supportive policies are propelling the red biotechnology testing market. The European Commission allocated €95.5 billion for Horizon Europe (2021-2027), with a significant portion dedicated to health research. These initiatives are fostering collaborations and accelerating market growth.

Growing Adoption of Next-Generation Sequencing (NGS):

The increasing adoption of Next-Generation Sequencing is driving growth in red biotechnology testing. The global NGS market size was valued at $6.3 billion in 2023, according to the National Center for Biotechnology Information. This technology is revolutionizing genetic testing and disease diagnosis.

Rising Focus on Biomarker Discovery:

The escalating focus on biomarker discovery is propelling advancements in red biotechnology testing. The FDA reported a 40% increase in biomarker-related submissions for drug approvals from 2020 to 2023. This trend is driving the development of novel diagnostic tools and targeted therapies.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Red Biotechnology Market Regional Analysis

Here is a more detailed regional analysis of the global red biotechnology market:

North America

North America dominates the global red biotechnology market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem.

According to the National Institutes of Health (NIH), the U.S. invested $45.1 billion in biomedical research in fiscal year 2023, fueling innovation in the sector.

This substantial funding has led to significant advancements in areas such as gene therapy and personalized medicine.

For instance, in February 15, 2024, Moderna announced the expansion of its mRNA pipeline, including 15 new programs in rare diseases and oncology, further solidifying North America's leadership in red biotechnology.

The region's market dominance is also driven by a high prevalence of chronic diseases and a supportive regulatory environment.

The Centers for Disease Control and Prevention (CDC) reported that 6 in 10 adults in the U.S. have a chronic disease as of 2023, creating a strong demand for innovative biotechnology solutions.

This demand is met by cutting-edge research and development efforts from industry leaders.

For instance, on September 8, 2023, Pfizer received FDA approval for its gene therapy treatment for hemophilia B, marking a significant milestone in red biotechnology applications and reinforcing North America's position at the forefront of the global market.

Asia Pacific

Asia Pacific is poised to emerge as the fastest-growing region in the global red biotechnology market during the forecast period, attributable by the by rapidly aging populations, increasing prevalence of chronic diseases, and rising disposable incomes.

According to the World Health Organization's Western Pacific Region office, healthcare expenditure in the region is projected to increase by 7.5% annually through 2025, driving demand for advanced biotechnology solutions.

For instance, in March 10, 2024, Takeda Pharmaceutical Company announced a $600 million investment to expand its biologics manufacturing capacity in Singapore, reinforcing the region's position as a key hub for red biotechnology.

The region's growth is further propelled by supportive government initiatives and improving healthcare infrastructure.

China's National Medical Products Administration (NMPA) reported a 35% increase in innovative medical device approvals in 2023 compared to the previous year, indicating a favorable regulatory environment for biotechnology advancements.

in addition to this, the emerging markets like India and South Korea are witnessing rapid adoption of personalized medicine approaches. For instance, in July 5, 2023, Samsung Biologics unveiled its new R&D Center in Songdo, South Korea, focusing on developing novel biologics and biosimilars to address unmet medical needs in the Asia Pacific region.

Global Red Biotechnology Market: Segmentation Analysis

The Global Red Biotechnology Market is segmented based on By Product Type, By Application, By End-User, and Geography.

Red Biotechnology Market, By Product Type

Monoclonal Antibodies
Polyclonal Antibodies
Recombinant
Proteins Vaccines
Others

Based on Product Type, the Global Red Biotechnology Market is bifurcated into Monoclonal Antibodies, Polyclonal Antibodies, Recombinant, Proteins Vaccines, Others. The monoclonal antibodies segment is currently dominating the global red biotechnology market, driven by their high specificity, sensitivity, and versatility. However, the recombinant proteins segment is growing at a rapid CAGR within the global red biotechnology market, fueled by advancements in genetic engineering and protein production technologies.

Red Biotechnology Market, By Application

Pharmacogenomics
Biopharmaceutical Production
Gene Therapy
Genetic Testing

Based on Application, the Global Red Biotechnology Market is bifurcated into Pharmacogenomics, Biopharmaceutical Production, Gene Therapy, Genetic Testing. The biopharmaceutical production segment is currently dominating the red biotechnology market, driven by the increasing demand for new and innovative drugs to treat various diseases. However, the gene therapy segment is experiencing rapid growth, fueled by advancements in gene editing technologies and the increasing potential of gene therapy to treat genetic disorders.

Red Biotechnology Market, By End-User

Research Institutes
CMOs & CROs
Biopharmaceutical Industries
Others

Based on End-User, the Global Red Biotechnology Market is bifurcated into Hospitals, Clinics, Insurance Companies, Government, Others. The biopharmaceutical industry is currently dominating the red biotechnology market, driven by the increasing demand for biologics in the treatment of chronic diseases and the rising investments in research and development by major pharmaceutical companies. However, the contract manufacturing organizations (CMOs) and contract research organizations (CROs) segment is experiencing rapid growth. These organizations provide specialized services to biopharmaceutical companies, such as manufacturing, clinical trials, and regulatory affairs.

Red Biotechnology Market, By Geography

North America
Europe
Asia Pacific
Rest of the world

Based on Geography, the Global Red Biotechnology Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominates the global red biotechnology market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem. However, the Asia Pacific is poised to emerge as the fastest-growing region in the global red biotechnology market during the forecast period, attributable by the by rapidly aging populations, increasing prevalence of chronic diseases, and rising disposable incomes.

Key Players

The "Global Red Biotechnology Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Hoffmann-La Roche, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Pfizer, Inc. , Biogen Inc. , Amgen Inc. and AstraZeneca Plc. and etc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Red Biotechnology Market Key Developments

In June 2022, CRISPR-Combo enables the editing of many genes in plants while modifying the expression of other genes, according to research from the University of Maryland's College of Agriculture and Natural Resources.
In September 2022, the US-FDA approved SKYSONA (elivaldogene autotemcel), often referred to as Eli-cel, in September 2022 for Bluebird Bio, Inc. to decrease the progression of neurologic deterioration in boys with early, active cerebral adrenoleukodystrophy (CALD) aged 4-17.

1 INTRODUCTION OF GLOBAL RED BIOTECHNOLOGY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
3.5 Market attractiveness

4 GLOBAL RED BIOTECHNOLOGY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL RED BIOTECHNOLOGY MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Monoclonal Antibodies
5.3 Polyclonal Antibodies
5.4 Recombinant
5.5 Protein Vaccines
5.6 Cell-based Immunotherapy Products
5.7 Gene Therapy Products
5.8 Cell Therapy Products
5.9Tissue-engineered Products
5.10 Stem Cells
5.11 Cell Culture
5.12 Viral Vector
5.13 Enzymes
5.14 Kits and Reagents
5.15 Animal Models
5.16 Molecular Diagnostics
5.17 Others

6 GLOBAL RED BIOTECHNOLOGY MARKET, BY APPLICATION

6.1 Overview
6.2 Pharmacogenomics
6.3 Biopharmaceutical Production
6.4 Gene Therapy
6.5 Genetic Testing

7 GLOBAL RED BIOTECHNOLOGY MARKET, BY END USER

7.1 Overview
7.2 Research Institutes
7.3 CMOs & CROs
7.4 Biopharmaceutical Industries
7.5 Others

8 GLOBAL RED BIOTECHNOLOGY MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL RED BIOTECHNOLOGY MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 ACE Matrix

10 COMPANY PROFILES

10.1 Amgen
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Gilead Sciences
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 AbbVie
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Johnson & Johnson
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Pfizer
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Merck & Co.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Roche
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Novartis
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Bristol Myers Squibb
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Takeda Pharmaceutical Company Limited
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments

11 KEY DEVELOPMENTS

11.1 Product Launches/Developments
11.2 Mergers and Acquisitions
11.3 Business Expansions
11.4 Partnerships and Collaborations

12 Appendix

12.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

全球红色生物技术市场规模：按产品类型、按应用、按最终用户、按地区、范围和预测

Global Red Biotechnology Market Size By Product Type (Gene Recombinant Drugs, Human Vaccines), By Application (Pharmacogenomics, Gene Therapy), By End-User (Research Institutes, Biopharmaceutical Industries), By Geographic Scope And Forecast

红色生物技术市场规模及预测

红色生物技术的世界市场动态

主要市场驱动因子

目录

第1章全球红色生物技术市场：简介

第 2 章执行摘要

第3章验证市场研究研究方法

第4章全球红色生物技术市场展望

第5章全球红色生物技术市场：依产品类型

第6章红色生物技术的全球市场：按应用划分

第 7 章红色生物技术全球市场：依最终用户划分

第 8 章全球红色生技市场：按地区

第9章全球红色生物科技市场竞争格局

第10章公司简介

第11章主要进展

第12章附录

Red Biotechnology Market Size and Forecast